CD274 and neoplasm: Multiple administrations of IL12 mRNA drug sequentially or concurrently with combination immunotherapy with anti-PD-L1 CPI, durvalumab were well tolerated for periods stretching to 2 years resulting in confirmed partial responses including at distant uninjected sites suggestive of abscopal, anti-tumor immune activation [43].